Navigation Links
InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
Date:1/5/2012

BRISBANE, Calif., Jan. 5, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced unaudited net sales of Esbriet® (pirfenidone) for the fourth quarter ended December 31, 2011, as well as information on the number of patients that initiated Esbriet therapy in Germany during 2011.  InterMune also highlighted its recent business and clinical development activities, including new efficacy data from the RECAP extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), and provided forward-looking operating expense guidance for 2012. 

Esbriet Launch in Germany 

InterMune estimates that approximately 612 patients have been prescribed Esbriet in Germany since the mid-September launch.  Of these 612 patients, approximately 172 patients were enrolled in the Named Patient Program (NPP) in Germany and were transitioned to commercial supply during the recently completed quarter.  The balance, or approximately 440 patients were prescribed Esbriet as new patients during the quarter. 

A total of 410 patients were enrolled in the NPP outside of Germany as of December 31, 2011, bringing the total number of new patient starts on Esbriet therapy across Europe to approximately 1,022 during 2011.

InterMune today reported that unaudited net sales of Esbriet in Germany during the fourth quarter of 2011 totaled approximately $2.7 million.  Unaudited net sales of Esbriet totaled approximately $2.8 million since its launch in mid-September 2011.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "We are extremely pleased that the German launch of Esbriet, the first commercial launch in Europe, continues to meet our high expectations both qualitatively and quantitatively.  These early results affirm our view that Esbriet has the potenti
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. InterMune Appoints Angus C. Russell to Board of Directors
2. InterMune to Release Third Quarter Financial Results on November 3
3. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
4. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
5. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
6. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
7. InterMune to Present at J.P. Morgan Healthcare Conference
8. InterMune Reports Third Quarter 2010 Financial Results
9. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
10. InterMune to Release Second Quarter Financial Results on July 27
11. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nk3569/future_horizons ... "Future Horizons and Growth Strategies in the European ... Forecasts" report to their offering. ... Blood Banking Market 2015 is a new five-countrystrategic ... and potential market entrants identify and evaluate emerging ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek Pharmaceuticals, ... focused on chronic inflammatory disease and neurologic disorders, announced ... study with anatabine citrate, the Company,s lead compound. Results ... of anatabine citrate can significantly inhibit the activation of ... Company is developing this compound in a Phase 1 ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3
... 12 CVS Caremark Corporation (NYSE: CVS ) today announced ... of approximately 15%, to 8.75 cents per share on the Common ... record on January 22, 2010 . This increase translates into an annual ... per share from the previous rate of 30.5 cents . , ...
... , ST. JOSEPH, Mich. , Jan. 12 ... announced today they have been awarded a $336K Phase I ... for creating a novel type of predictive signatures for drug ... should overcome many shortcomings of existing methods of molecular diagnostics. ...
Cached Medicine Technology:CVS Caremark Corporation Increases Quarterly Dividend 15% 2GeneGo Receives SBIR Grant 2GeneGo Receives SBIR Grant 3
(Date:7/1/2015)... ... July 01, 2015 , ... ... of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. ... West Virginia on June 26th, the Court rejected the Plaintiff’s assertion that ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... today announced that they will welcome four new members to their industry leading ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... natural forms, such as organically raised chickens and eggs. Eating organic foods and ... chickens is cleaner and more environmentally friendly than production chicken farming. Choosing home ...
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 , ... ... $100,000 from the New York Community Trust. The grant will allow CCF to improve ... sharing proven practices. , CCF was formed to respond to many changes in New ...
(Date:7/1/2015)... NY (PRWEB) , ... July 01, 2015 , ... Summer ... taboo with teenagers to fix noses and chins with plastic surgery when they’re looking ... Surgeons (ASPS) more than 236,000 cosmetic procedures were performed on patients ages 19 and ...
Breaking Medicine News(10 mins):Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 2Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 3
... The Breast, Cancer Patient Protection Act, Championed by ... DeLauro (D-CT) and Moran (R-KS) -, - Effort Part ... Campaign to Encourage Women to Speak Out on Issues That ... a Capitol Hill,press conference, actress Marcia Cross joined Lifetime and ...
... reward center, which can go awry , , WEDNESDAY, Jan. ... specific part of the brain handles what might be ... could lead scientists closer to more effective treatments for ... a brain region is helpful because it provides insight ...
... that field mice have evolved a unique way of ensuring ... infertility in humans. , The team, in collaboration with ... their immunity protection in favour of a more rapid fertilisation ... protein, called CD46. Present in both animals and humans, ...
... week cut death risk in half, study found , , WEDNESDAY, ... of exercise can dramatically prolong a man,s life, new research ... analysis -- the largest such study ever -- found that ... least four to six days a week was enough to ...
... KIRKLAND, Wash., Jan. 23 "A failing mind, ... care today," says Cameron,Truesdell, CEO of LTC Financial Partners, ... shouldn,t be, so we,re going to give,our clients information ... is offering a free guidebook and web links to ...
... Label Highlights CLARITIN Effectively Treats Indoor and ... Schering-Plough,(NYSE: SGP ) today announced ... has,approved additional labeling for CLARITIN(R) (loratadine), which ... relieves,allergy symptoms caused by both indoor (also ...
Cached Medicine News:Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 2Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 3Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 4Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 5Health News:Specific Brain Region Governs Problem-Solving Skills 2Health News:Specific Brain Region Governs Problem-Solving Skills 3Health News:Evolutionary phenomenon in mice may explain human infertility 2Health News:A Little Regular Exercise Extends Men's Lives 2Health News:A Little Regular Exercise Extends Men's Lives 3Health News:Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims 2Health News:FDA Approves Labeling Change for Non-Drowsy CLARITIN(R) 2Health News:FDA Approves Labeling Change for Non-Drowsy CLARITIN(R) 3
2.5 mm x 0.6 mm. Overall length: 122 mm, 4.8 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: